MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Cellares
Organization & Developments: Cellares
Parents
Cellares
Children
*Cellares is developing a scalable, end-to-end automated solution for industrial cell therapy manufacturing.
*The company’s “factory-in-a-box” utilizes robust and reproducible cell processes that can deliver real cost savings, improved efficiency, and true scalability.
2024: Cellares launched Cell Q, which the company touted as the world’s first automated quality control work unit for cell therapy manufacturing.
2024: Cellares, which has dubbed itself the world’s first integrated development and manufacturing organization (IDMO), has a setup that allows it to produce cell therapy batches with 90% less labor and facility space than conventional CDMOs, with a 50% lower batch price.
2024: With $380M deal, Bristol Myers Squibb ups the ante with cell therapy manufacturer Cellares
2025: Inside the futuristic biotech startup Cellares that’s building a cure for cancer with $355 million in funding
Jumps
Finance & Acquisition: Cellares
Key People: Cellares